[1] YANG G,WANG Y,ZENG Y,et al. Rapid health transition in China,1990-2010:findings from the Global Burden of Disease Study 2010[J]. Lancet,2013,381(9882):1987-2015. [2] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in china,2015[J]. CA Cancer J Clin,2016,66(2):115-132. [3] COLLABORATION N C. Trends in adult body-mass index in 200 countries from 1975 to 2014:a pooled analysis of 1698 population-based measurement studies with 19.2 million participants[J]. Lancet,2016,387(10026):1377-1396. [4] AUNE D,GREENWOOD D C,CHAN D S,et al. Body mass index,abdominal fatness and pancreatic cancer risk:a systematic review and non-linear dose-response meta-analysis of prospective studies[J]. Ann Oncol,2012,23(4):843-852. [5] LI D,MORRIS J S,LIU J,et al. Body mass index and risk,age of onset,and survival in patients with pancreatic cancer[J]. JAMA,2009,301(24):2553-2562. [6] FONT-BURGADA J,SUN B,KARIN M. Obesity and cancer:the oil that feeds the flame[J]. Cell Metab,2016,23(1):48-62. [7] IACOBUZIO-DONAHUE C A,VELCULESCU V E,WOLFGANG C L,et al. Genetic basis of pancreas cancer development and progression:insights from whole-exome and whole-genome sequencing[J]. Clin Cancer Res,2012,18(16):4257-4265. [8] IACOBUZIO-DONAHUE C A. Genetic evolution of pancreatic cancer:lessons learnt from the pancreatic cancer genome sequencing project[J]. Gut,2012,61(7):1085-1094. [9] PEREZ-MANCERA P A,GUERRA C,BARBACID M,et al. What we have learned about pancreatic cancer from mouse models[J]. Gastroenterology,2012,142(5):1079-1092. [10] FORBES S A,BEARE D,BOUTSELAKIS H. Catalogue of somatic mutations in cancer:Cosmic v83[DB/OL]. 2017,http://cancer.sanger.ac.uk/cosmic. [11] KYRGIOU M,KALLIALA I,MARKOZANNES G,et al. Adiposity and cancer at major anatomical sites:umbrella review of the literature[J]. BMJ,2017,356:j477. [12] INCIO J,TAM J,RAHBARI N N,et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity[J]. Clin Cancer Res,2016,22(12):2993-3004. [13] INCIO J,LIU H,SUBOJ P,et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy[J]. Cancer Discov,2016,6(8):852-869. [14] GALLAGHER E J,LEROITH D. The proliferating role of insulin and insulin-like growth factors in cancer[J]. Trends Endocrinol Metab,2010,21(10):610-618. [15] SPENTZOS D,CANNISTRA S A,GRALL F,et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer[J]. Endocr Relat Cancer,2007,14(3):781-790. [16] HAILEY J,MAXWELL E,KOUKOURAS K,et al. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells[J]. Mol Cancer Ther,2002,1(14):1349-1353. [17] SACHDEV D,LI S L,HARTELL J S,et al. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I[J]. Cancer Res,2003,63(3):627-635. [18] GOETSCH L,GONZALEZ A,LEGER O,et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts[J]. Int J Cancer,2005,113(2):316-328. [19] RAY A,NKHATA K J,CLEARY M P. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status[J]. Int J Oncol,2007,30(6):1499-1509. [20] LIU H,MA Q,LI J. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells[J]. Mol Cell Biochem,2011,347(1/2):95-101. [21] WANG Y,LAM J B,LAM K S,et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice[J]. Cancer Res,2006,66(23):11462-11470. [22] TANG C H,LU M E. Adiponectin increases motility of human prostate cancer cells via adipoR,p38,AMPK,and NF-kappaB pathways[J]. Prostate,2009,69(16):1781-1789. [23] JACKSON L,WAHLI W,MICHALIK L,et al. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer[J]. Gut,2003,52(9):1317-1322. [24] DONMEZ-ALTUNTAS H,SAHIN F,BAYRAM F,et al. Evaluation of chromosomal damage,cytostasis,cytotoxicity,oxidative DNA damage and their association with body-mass index in obese subjects[J]. Mutat Res Genet Toxicol Environ Mutagen,2014,771:30-36. [25] FERNANDEZ-SANCHEZ A,MADRIGAL-SANTILLAN E,BAUTISTA M,et al. Inflammation,oxidative stress,and obesity[J]. Int J Mol Sci,2011,12(5):3117-3132. [26] HEYDARI A R,UNNIKRISHNAN A,LUCENTE L V,et al. Caloric restriction and genomic stability[J]. Nucleic Acids Res,2007,35(22):7485-7496. [27] SPINDLER S R. Rapid and reversible induction of the longevity,anticancer and genomic effects of caloric restriction[J]. Mech Ageing Dev,2005,126(9):960-966. [28] BIANKIN A V,WADDELL N,KASSAHN K S,et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes[J]. Nature,2012,491(7424):399-405. [29] KANDA M,MATTHAEI H,WU J,et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia[J]. Gastroenterology,2012,142(4):730-733. [30] JONES S,ZHANG X,PARSONS D W,et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. Science,2008,321(5897):1801-1806. [31] HOSODA W,CHIANCHIANO P,GRIFFIN J F,et al. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4[J]. J Pathol,2017,242(1):16-23. |